ABSTRACT Postmenopausal osteoporosis is caused by excessive osteoclast‐mediated bone resorption. This study identifies mitochondrial oxidative phosphorylation (OXPHOS) as a tractable metabolic target for antiresorptive therapy. A literature‐guided drug repurposing screen focused on compounds reported to affect OXPHOS o...
Hai-Bo Liang, Yong Xiao, Jiang-Tao Luo et al.· Advancement of science· 0 citations
Current antiresorptive therapies reduce bone loss by eliminating osteoclasts or inhibiting their formation. However, these approaches could disrupt osteoclast-osteoblast communication and cause serious complications with long-term usage. There is a need for developing new therapies that selectively inhibit resorptive f...
Yihe Li, Qi-Hang Wu, Shengnan Qin et al.· Journal of Bone and Mineral...· 0 citations
The results suggest that CVB suppresses osteoclastogenesis and their resorptive function through modulation of MAPK and PI3K/AKT/FOXO1 pathways and by enhancing antioxidant defense, which has potential therapeutic value for antiosteoporosis treatment.
Qiu-Fei Li, Na Hai, Jin-Deng Liao et al.· Journal of Agricultural and...· 0 citations
It is confirmed that ERI maintains bone homeostasis by regulating PINK1/Parkin-mediated mitophagy and suppressing NLRP3 inflammasome activation, which may provide a novel natural candidate for the treatment of bone loss-related diseases.
Yi-Yuan Wang, Wen Pu, Yuangang Su et al.· Pharmacological Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.